163 related articles for article (PubMed ID: 7083217)
1. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology.
Sparano BM; Gordon G; Hall C; Iatropoulos MJ; Noble JF
Cancer Treat Rep; 1982 May; 66(5):1145-58. PubMed ID: 7083217
[TBL] [Abstract][Full Text] [Related]
2. The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin.
Tham P; Dougherty W; Iatropoulos MJ; Gordon G; James VC; Hall C; Noble JF
Am J Pathol; 1987 Jul; 128(1):121-30. PubMed ID: 3605309
[TBL] [Abstract][Full Text] [Related]
3. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.
Henderson BM; Dougherty WJ; James VC; Tilley LP; Noble JF
Cancer Treat Rep; 1982 May; 66(5):1139-43. PubMed ID: 7083216
[TBL] [Abstract][Full Text] [Related]
4. Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig.
Perkins WE; Schroeder RL; Carrano RA; Imondi AR
Cancer Treat Rep; 1984 Jun; 68(6):841-7. PubMed ID: 6733698
[TBL] [Abstract][Full Text] [Related]
5. Effect of thyroid hormone supplementation on chronic doxorubicin (adriamycin)-induced cardiotoxicity and serum concentrations of T3 and T4 in dogs.
Van Vleet JF; Ferrans VJ; Badylak SF
Am J Vet Res; 1982 Dec; 43(12):2173-82. PubMed ID: 6891885
[TBL] [Abstract][Full Text] [Related]
6. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study.
Koutinos G; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(2A):815-20. PubMed ID: 12014656
[TBL] [Abstract][Full Text] [Related]
7. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
8. Cardiac evaluation of mitoxantrone.
Unverferth DV; Unverferth BJ; Balcerzak SP; Bashore TA; Neidhart JA
Cancer Treat Rep; 1983 Apr; 67(4):343-50. PubMed ID: 6850653
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
10. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.
Kanter PM; Bullard GA; Ginsberg RA; Pilkiewicz FG; Mayer LD; Cullis PR; Pavelic ZP
In Vivo; 1993; 7(1):17-26. PubMed ID: 8504204
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
[TBL] [Abstract][Full Text] [Related]
13. [Experimental study of the subacute toxicity of mitoxantrone and doxorubicin in rats (subcutaneous and/or intraperitoneal route)].
Bouhour JB; Chiffoleau S; Delajartre AY
Arch Mal Coeur Vaiss; 1986 Jul; 79(8):1238-44. PubMed ID: 3096251
[TBL] [Abstract][Full Text] [Related]
14. Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone.
Crescimanno M; Flandina C; Rausa L; Sanguedolce R; D'Alessandro N
Chemioterapia; 1988 Feb; 7(1):53-9. PubMed ID: 3163942
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
16. Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.
Pratt CB; Crom DB; Wallenberg J; Sanyal SK; Miliauskas J; Sohlberg K
Cancer Treat Rep; 1983 Jan; 67(1):85-8. PubMed ID: 6684503
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
18. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin affects both the number and the morphology of specific atrial granules in dog heart.
Bellini O; Danesi R; Bernardini N; Cardini G; Marzilli M; del Tacca M
Anticancer Res; 1988; 8(4):599-604. PubMed ID: 3178151
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
